

Special Issue

Inequality in Immunization 2023

Message from the Guest Editors

While overall in the world, immunization rates stagnated prior to the COVID-19 pandemic, and declined in 2020 and 2021, this is neither uniformly the case for all types of vaccines, nor for all population sub-groups for any individual vaccine. In this Special Issue, we will explore the latest evidence on various types of immunization across the life course at global, regional, national and subnational levels. We encourage submissions that explore various dimensions of inequality—such as economic status, subnational geographic regions, sex, maternal education—and other categories (like migrant status or occupation), or that shed greater analytical or methodological light on priority population subgroups, namely, populations facing gender barriers, rural residents, the urban poor, and populations living in conflict areas. We encourage submissions that compare various country contexts or that assess trends over time, and those that draw from geographies where the evidence has been limited to date, such as Low and Middle-Income Country contexts. Communications that describe the impacts of inequality monitoring of immunization are also welcome.

Guest Editors

Dr. Ahmad Reza Hosseinpoor

Dr. M. Carolina Danovaro

Dr. Devaki Nambiar

Dr. Aaron Wallace

Dr. Hope L. Johnson

Deadline for manuscript submissions

closed (28 February 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/134476

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).